Genmab A/S, a biotechnology firm based in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody-based treatments for various forms of cancer and other serious conditions. The company currently commercializes several key therapeutic antibodies. DARZALEX (daratumumab) is utilized in the treatment of multiple myeloma (MM), specific non-MM blood cancers, and AL amyloidosis. Other marketed offerings include teprotumumab for thyroid eye disease, ofatumumab, which addresses chronic lymphocytic leukemia (CLL) and multiple sclerosis, and Amivantamab for advanced or metastatic non-small cell lung cancer (NSCLC) as well as gastric or esophageal cancers. Genmab maintains an extensive and active development pipeline, featuring a broad range of experimental therapies. This includes GEN1047, tisotumab vedotin (targeting cervical, ovarian, and other solid cancers), and bispecific antibodies such as DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB, which are engineered for solid tumors. Epcoritamab is being developed for relapsed/refractory diffuse large B-cell lymphoma and CLL, while HexaBody-CD38 and DuoHexaBody-CD37 are designed to treat hematological malignancies. Further assets in the pipeline encompass Teclistamab, currently in Phase 2 clinical trials for vaso-occlusive crises, Camidanlumab tesirine for Hodgkin lymphoma and solid tumors, JNJ-64007957 and JNJ-64407564 for MM, PRV-015 for celiac disease, Mim8 for haemophilia A, and Lu AF82422 for multiple system atrophy. Additionally, the company is engaged in approximately 20 pre-clinical research programs. Strategic collaborations are a cornerstone of Genmab's operational model. It holds a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. The company also partners with CureVac AG on the research and development of mRNA-based antibody products, with argenx for the discovery of novel therapeutic antibodies in immunology and oncology, and with AbbVie for the development of epcoritamab. Other notable collaborators include BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was established in 1999 and is headquartered in Copenhagen, Denmark.
前收盘价
US$50.60
−US$0.75 · -1.46%
盘中时间采用ET。市场数据可能有所延迟。
Genmab A/S, a biotechnology firm based in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody-based treatments for various forms of cancer and other serious conditions. The company currently commercializes several key therapeutic antibodies. DARZALEX (daratumumab) is utilized in the treatment of multiple myeloma (MM), specific non-MM blood cancers, and AL amyloidosis. Other marketed offerings include teprotumumab for thyroid eye disease, ofatumumab, which addresses chronic lymphocytic leukemia (CLL) and multiple sclerosis, and Amivantamab for advanced or metastatic non-small cell lung cancer (NSCLC) as well as gastric or esophageal cancers. Genmab maintains an extensive and active development pipeline, featuring a broad range of experimental therapies. This includes GEN1047, tisotumab vedotin (targeting cervical, ovarian, and other solid cancers), and bispecific antibodies such as DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB, which are engineered for solid tumors. Epcoritamab is being developed for relapsed/refractory diffuse large B-cell lymphoma and CLL, while HexaBody-CD38 and DuoHexaBody-CD37 are designed to treat hematological malignancies. Further assets in the pipeline encompass Teclistamab, currently in Phase 2 clinical trials for vaso-occlusive crises, Camidanlumab tesirine for Hodgkin lymphoma and solid tumors, JNJ-64007957 and JNJ-64407564 for MM, PRV-015 for celiac disease, Mim8 for haemophilia A, and Lu AF82422 for multiple system atrophy. Additionally, the company is engaged in approximately 20 pre-clinical research programs. Strategic collaborations are a cornerstone of Genmab's operational model. It holds a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. The company also partners with CureVac AG on the research and development of mRNA-based antibody products, with argenx for the discovery of novel therapeutic antibodies in immunology and oncology, and with AbbVie for the development of epcoritamab. Other notable collaborators include BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was established in 1999 and is headquartered in Copenhagen, Denmark.
日内区间
当前US$50.60
52周区间
当前US$50.60
盘中时间采用ET。市场数据可能有所延迟。
Genmab A/S, a biotechnology firm based in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody-based treatments for various forms of cancer and other serious conditions. The company currently commercializes several key therapeutic antibodies. DARZALEX (daratumumab) is utilized in the treatment of multiple myeloma (MM), specific non-MM blood cancers, and AL amyloidosis. Other marketed offerings include teprotumumab for thyroid eye disease, ofatumumab, which addresses chronic lymphocytic leukemia (CLL) and multiple sclerosis, and Amivantamab for advanced or metastatic non-small cell lung cancer (NSCLC) as well as gastric or esophageal cancers. Genmab maintains an extensive and active development pipeline, featuring a broad range of experimental therapies. This includes GEN1047, tisotumab vedotin (targeting cervical, ovarian, and other solid cancers), and bispecific antibodies such as DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB, which are engineered for solid tumors. Epcoritamab is being developed for relapsed/refractory diffuse large B-cell lymphoma and CLL, while HexaBody-CD38 and DuoHexaBody-CD37 are designed to treat hematological malignancies. Further assets in the pipeline encompass Teclistamab, currently in Phase 2 clinical trials for vaso-occlusive crises, Camidanlumab tesirine for Hodgkin lymphoma and solid tumors, JNJ-64007957 and JNJ-64407564 for MM, PRV-015 for celiac disease, Mim8 for haemophilia A, and Lu AF82422 for multiple system atrophy. Additionally, the company is engaged in approximately 20 pre-clinical research programs. Strategic collaborations are a cornerstone of Genmab's operational model. It holds a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. The company also partners with CureVac AG on the research and development of mRNA-based antibody products, with argenx for the discovery of novel therapeutic antibodies in immunology and oncology, and with AbbVie for the development of epcoritamab. Other notable collaborators include BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was established in 1999 and is headquartered in Copenhagen, Denmark.
日内区间
当前US$50.60
52周区间
当前US$50.60
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目(USD) | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 37.23亿 USD | 215.26亿 USD | 164.74亿 USD | 145.05亿 USD | 84.17亿 USD |
| 销货成本 | 3.09亿 USD | 9.85亿 USD | 2.26亿 USD | — | — |
| 毛利 | 34.14亿 USD | 205.41亿 USD | 162.48亿 USD | 145.05亿 USD | 84.17亿 USD |
| 研究与开发 | 15.6亿 USD | 97.48亿 USD | 76.3亿 USD | 55.62亿 USD | 41.81亿 USD |
| 销售、一般及管理费用 | 6.02亿 USD | 37.9亿 USD | 32.97亿 USD | 26.76亿 USD | 12.83亿 USD |
| 营业费用 | 21.63亿 USD | 138.38亿 USD | 109.27亿 USD | 82.38亿 USD | 54.64亿 USD |
| 利息收入 | 1.38亿 USD | 9.95亿 USD | 9.39亿 USD | 3.24亿 USD | 1.97亿 USD |
| 利息支出 | 6104.81万 USD | 1.2亿 USD | 2700万 USD | 2100万 USD | 1300万 USD |
| 折旧和摊销 | 7105.6万 USD | 4.13亿 USD | 2.94亿 USD | 3.62亿 USD | 2.49亿 USD |
| 营业利润 | 12.51亿 USD | 67.03亿 USD | 53.21亿 USD | 62.67亿 USD | 29.53亿 USD |
| 净利润 | 9.64亿 USD | 78.44亿 USD | 43.52亿 USD | 54.52亿 USD | 29.57亿 USD |
公司数据更新于 2026年11月22日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
报告持有此股票敞口的交易所交易基金。
iShares Biotechnology ETFIBB2.17亿2.07%105.27亿 USD0.44%US$199.54—
First Trust NYSE Arca Biotechnology Index FundFBT1.35亿4.70%28.67亿 USD0.55%US$257—
Avantis International Equity ETFAVDE2667.21万0.14%183.06亿 USD0.23%US$82.46—
Tema Oncology ETFCANC1260.64万6.49%——US$37.5165—
First Trust Nasdaq BuyWrite Income ETFFTQI355.49万0.40%8.94亿 USD0.75%US$19.46—
Harding Loevner International Developed Markets Select Equity ETFLOEV289.51万3.53%——US$14.98—
John Hancock Investments - Multifactor Developed International ETFJHMD274.58万0.29%9.42亿 USD0.39%US$41.50—
Fidelity Nasdaq Composite Index ETFONEQ136.59万0.01%104.5亿 USD0.21%US$89.52—
iShares Biotechnology ETFIBB
First Trust NYSE Arca Biotechnology Index FundFBT
Avantis International Equity ETFAVDE
Tema Oncology ETFCANC
First Trust Nasdaq BuyWrite Income ETFFTQI
Harding Loevner International Developed Markets Select Equity ETFLOEV
John Hancock Investments - Multifactor Developed International ETFJHMD
Fidelity Nasdaq Composite Index ETFONEQAI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。